# Song et al. 2025 - Data Pooling Strategy in Multi-Regional Clinical Trials

## Citation
Song, J., Ji, C., Chen, M., Dong, J., Zhu, C., Wu, H., Zhang, W., Zhang, K., Yu, B., Wang, Y., Zhang, H., Jia, F. & Hou, Y. (2025) "Basic Considerations for Data Pooling Strategy in Multi-Regional Clinical Trials (MRCTs)" *Therapeutic Innovation & Regulatory Science*, 59:359-364.
DOI: [10.1007/s43441-025-00744-8](https://doi.org/10.1007/s43441-025-00744-8)

## Summary

This paper from the China NMPA perspective describes practical considerations for implementing ICH E17 data pooling strategies in multi-regional clinical trials. It provides a decision flowchart for pooling strategy determination and discusses effect modifier identification, statistical models for evaluating effect size, and regulatory considerations specific to China and East Asia.

## Key Contributions

1. **Practical flowchart**: Step-by-step decision process for pooling strategy
2. **China/East Asia focus**: Specific considerations for regional pooling in Asia
3. **Effect modifier guidance**: Practical approach to EM identification
4. **Regulatory perspective**: NMPA implementation of ICH E17

## Pooling Strategy Framework

### Two Main Strategies (from ICH E17)

1. **Pooled regions**: "Pooling some geographical regions, countries or regulatory regions at the planning stage, if subjects in those regions are thought to be similar enough with respect to intrinsic and/or extrinsic factors relevant to the disease and/or drug under study."

2. **Pooled subpopulations**: "Pooling a subset of the subjects from a particular region with similarly defined subsets from other regions whose members share one or more intrinsic or extrinsic factors important for the drug development programme at the planning stage."

### Decision Flowchart (Figure 1)

```
[Explore and identify intrinsic and extrinsic factors]
                    ↓
        [Identify true effect modifiers]
                    ↓
         ─────Yes────┬────No─────
                     ↓            ↓
    [Pooling of subpopulations]  [Pooling of regions]
                                      ↓
                    [No evidence of differences across East Asian populations]
                         ─────Yes────┬────No─────
                                     ↓            ↓
              [Pooling of East Asia populations]  [No pooling]
```

## Effect Modifier Identification

### Key Principle
> "EMs need to be determined and identified from intrinsic and extrinsic factors which might have the impact to the drug on specific populations."

### Intrinsic Factors
- Pharmacokinetics and pharmacodynamics
- Genetic data, biomarkers
- Ethnicity

### Extrinsic Factors
- Medical practice, concomitant medications
- Diet, environmental factors
- Healthcare systems

### Data Sources for EM Identification
1. Phase I clinical studies (especially bridging studies)
2. Early clinical trials
3. Epidemiological data
4. Real-world data
5. Historical trials of similar drugs

## Statistical Models for Effect Size

The paper describes three approaches:

### 1. Simple Pooling
Direct pooling with descriptive summary on baseline data, efficacy, safety across pooled populations.

### 2. Fixed-Effect Model
Assumes average treatment effects across pooled populations are the same. Uses weighted average approach.

### 3. Random-Effect Model
Assumes randomly varying effect across populations. Used when there is heterogeneity between trials or populations.

## Relevance to nABCD

### Direct Application
nABCD addresses the key gap identified in this paper:

> "It is extremely challenging to identify the true EMs. When the true EMs cannot be identified, we choose instead the region pooling strategy."

nABCD provides **quantitative assessment** of EM distribution similarity to support this decision.

### Specific Connections

1. **EM distribution comparison**: nABCD directly measures what this paper discusses qualitatively
2. **China vs non-China pooling**: nABCD can quantify Japan-China-Korea EM similarities
3. **Threshold for pooling**: Paper lacks specific threshold; nABCD provides one (< 0.15)

### Quote for Introduction
> "If no EMs are found, we use pooling by regions to understand whether differences across East Asian population exists, and whether pooling by East Asian is necessary."

This is exactly what nABCD addresses!

## Data Borrowing

The paper discusses external data integration:
- Bayesian methods for borrowing from different sources
- Propensity score matching for confounding
- Important when Chinese population sample is limited

## Limitations of Paper

1. **No specific metric**: Discusses pooling qualitatively, no quantitative similarity measure
2. **Threshold missing**: No guidance on "how similar is similar enough"
3. **Statistical details sparse**: Limited mathematical framework

## Tags
ICH E17, MRCT, data pooling, effect modifier, China NMPA, East Asia, regional pooling, subpopulation pooling, nABCD application

---
*Processed by Rachel Zane | 2026-02-02*
*Priority: P1 - Direct application context for nABCD*
